Progenity to Report Third Quarter 2021 Financial Results and Provide Corporate Update
Rhea-AI Summary
Progenity, Inc. (NASDAQ: PROG) will announce its third quarter 2021 financial results on November 10, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results and provide updates. Progenity focuses on innovative biotechnology solutions in women’s health, gastrointestinal health, and oral biotherapeutics, using a multi-omics approach to enhance disease diagnostics and patient care.
Positive
- Innovative biotechnology focus on women's and gastrointestinal health.
- Plans to provide corporate updates alongside financial results.
Negative
- None.
News Market Reaction – PROG
In the trading session that priced this news, PROG declined 8.53%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), an innovative biotechnology company, today announced that it will report third quarter 2021 financial results on Wednesday, November 10, 2021 after the close of financial markets. Progenity’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 833-519-1237 for domestic callers or 914-800-3810 for international callers, and entering the conference code: 9763335. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.progenity.com.
About Progenity
Progenity, Inc. is a biotechnology company innovating in the fields of women’s health, gastrointestinal health and oral biotherapeutics. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.
For more information visit www.progenity.com, or follow the company on LinkedIn or Twitter.
Investor Contact:
Robert Uhl
Managing Director, ICR Westwicke
ir@progenity.com
(619) 228-5886
Media Contact:
Kate Blom-Lowery
CG Life
media@progenity.com
(858) 457-2436
